Reported Saturday, MODULAR ATP Study Of Boston Scientific's mCRM System Meets Safety And Efficacy Endpoints
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific's mCRM System, including the EMPOWER LP pacemaker and EMBLEM S-ICD System, has met all six-month safety and efficacy endpoints in the MODULAR ATP study. Key findings include a 97.5% major complication-free rate, 98.8% communication success rate, and 61.3% ATP success rate.
May 20, 2024 | 5:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Boston Scientific's mCRM System, including the EMPOWER LP pacemaker and EMBLEM S-ICD System, has met all six-month safety and efficacy endpoints in the MODULAR ATP study. This positive outcome is likely to boost investor confidence and potentially drive the stock price up in the short term.
The successful results from the MODULAR ATP study demonstrate the safety and efficacy of Boston Scientific's mCRM System, which is likely to enhance investor confidence and positively impact the stock price. The high success rates in key metrics such as major complication-free rate and communication success rate are particularly noteworthy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100